
Royalty Pharma plc (RPRX)
Last updated: 2026-10-20 18:19:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Royalty Pharma plc (RPRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $62.24, with a market capitalization of $27.14B and a P/E ratio of 32.93. Over the past 52 weeks, its price has ranged from $35.92 to $64.38. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$27.14B | |
$60.92 | |
$64.38 | |
$0.26 | |
$60.27 | |
958.71K | |
2.98M | |
32.93 | |
$64.38 | |
$35.92 | |
1.49% | |
-- |
Royalty Pharma plc (RPRX) Stock Price Today
Royalty Pharma plc (RPRX) is currently trading at $62.24 as of 2026-10-20 18:02:17, up 3.27% ($1.97) from the previous close of $60.27
During today's regular trading session, RPRX has traded between $0.26 and $64.38, with a trading volume of 958.71K shares. The current price is near the upper end of today's range.
Royalty Pharma plc (RPRX) 7-Day Stock Price Change
Over the past seven days, Royalty Pharma plc (RPRX) moved from $56.93 to $62.24, representing a gain of 9.33% ($5.31).
The stock traded between $55.72 and $62.27 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 3.39 million shares, up versus the previous seven-day period, indicating higher trading activity.
RPRX 52-Week Price Position
Position in Range: 92.5%
RPRX is currently trading at $62.24, placing it 92.5% of the way from its 52-week low of $35.92 to its 52-week high of $64.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Royalty Pharma plc (RPRX)?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma plc Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 100 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Royalty Pharma plc (RPRX) Stock on MEXC
Eligible investors can buy real shares of Royalty Pharma plc (RPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Royalty Pharma plc (RPRX) stock price today?
2.Is RPRX stock going up or down today?
3.What is RPRX pre-market price?
4.What is RPRX after-hours price?
5.Is RPRX stock trading now?
6.Where does RPRX sit relative to its 52-week high and low?
7.What sector is Royalty Pharma plc in?
8.What is Royalty Pharma plc's market capitalization and where is it listed?
9.How is RPRX valued in terms of P/E ratio and EPS?
10.Does Royalty Pharma plc pay a dividend?
Explore More US Stocks
Search Stocks
RPRX Stock Calculator
Estimate the value between RPRX shares and USD.
RPRX Shares to USD
1.00 RPRX shares = 62.242 USD
Calculations are estimates based on the latest available price and are for reference only.



